(1) Bioresource Overview
The Bimetra Biobank is the central high-quality biorepository of Bimetra, the Clinical Research Centre (CRC) . Bimetra was established in 2010 as central point of contact (CPOC) for facilitation of translational biomedical research within Ghent University Hospital in collaboration with Ghent University. The mission of Bimetra is to reinforce the translation from basic research discovery studies to validation studies and clinical trials by creating an effective ‘discovery-to-care continuum’ towards healthcare innovation. Being able to build upon resources is key in accelerating translation and strengthening the position of Academic Health Centres. To achieve this goal, Bimetra is organised in five specialized platforms to facilitate specific research aspects (Figure 1).
Bimetra Biobank is a central biorepository at Ghent University Hospital, facilitating all aspects related to high quality sample processing, storage and distribution. Bimetra biobank acts as a core facility for local researchers and third parties in need of high quality biobanking. Local strategic prospective collections, important historical collections and interuniversity focus collections are operationally managed within the biobank. The collections in the Bimetra Biobank are diverse, ranging from disease-based clinical to population-based cohort collections, besides a cell line catalogue. A detailed overview of collections hosted at Bimetra Biobank can be found below under bioresource type.
The day-to-day operational management of Bimetra Biobank is performed by the biobank manager under supervision of the Head of Department of Bimetra. Sample processing, storage and associated data management is performed by the lab technicians. For each particular primary collection a coordinator (MD) is appointed, responsible for interactions with donors (ICF, sample prelevation, incidental findings, secondary use). For general/central collaborative collections, the coordinator confers with an advisory committee of specialists regarding sample requests. E.g. for the tumour biobank collection, the tumour biobank coordinator confers with the multidisciplinary cancer-specific oncological advisory committee. The biobank manager facilitates sample requests handling in interaction with collection coordinators to ascertain approval for sample release. A general hospital biobank coordinator was appointed to oversee compliance with all applicable laws, policies and regulations.
An overview of the governance structure of Bimetra Biobank is described in Figure 2.
Bimetra Biobank is part of the Flemish Biobank Network (Centre for Medical Innovation (CMI)), within the Belgian node BBMRI.be of the European Biobank Network BBMRI-ERIC. The Flemish Biobank Network was officially founded in December 2009 through a collaborative effort between the Flemish Government, the Flemish Ministry of Economy and Scientific Affairs, the 5 universities and the 4 university hospitals and representatives of the Healthcare Industry. Bimetra Biobank together with each university hospital in this Network was able to set up a central high quality repository facility by 2015 through a one-off governmental funding (8 M EUR for all collaborating centres in total and matching funds from the participating institutions). The initiation of the Flemish Biobank Network and available funding led to jointly set up local biobank infrastructures within a harmonized quality framework, according to ethical and legal requirements, with common access procedures and an integrated interuniversity catalogue  of available samples. A uniform quality management system was implemented within this Network according to the International Society for Biological and Environmental Repositories (ISBER) Best Practices for Repositories Guidelines  and Organisation for Economic Co-operation and Development (OECD) guidelines for biorepositories  and is adapted for storage of different sample types in controlled and temperature monitored Ultra Low Temperature (ULT) devices and isothermal freezers. Besides cryogenic storage capacity, Bimetra Biobank has established a laboratory for sample processing (e.g. serum separation, buffy coat preparation, Quality Control (QC), Formalin-Fixed Paraffin Embedded (FFPE) slide and cryosection preparation, isolation of nucleic acids) which follows Good Laboratory Practices (GLP). The laboratory is located next to the storage facility, in order to minimize critical transportation time of samples. All samples are registered in the biobank management system, SLims (from Genohm)  with an associated minimal dataset, including International Statistical Classification of Diseases and Related Health Problems codes (ICD-10) and International Classification of Diseases for Oncology (ICD-O3) codes, both established by the World Health Organization (WHO). This is supplemented with the sample pre-analytical data to automatically generate the Standard PREanalytical code (SPREC) . The flexibility of our biobank management system with integrated Electronic Lab Notebook (ELN) system allows for easy automated collection of the parameters needed for the SPREC coding linked with information from various other databases. Throughout all collections minimal datasets are used, often linked to larger collection specific datasets making the datasets very valuable. In addition, the quality management system is provided with a document control system for Standard Operating Procedures (SOPs). Bimetra Biobank is partner of Biobanking and Biomolecular Resources Research Infrastructure (BBMRI.be), and therefore the collections of the Bimetra Biobank are accessible through the BBMRI.EU sample locator.
Human (Homo sapiens).
Biological samples and associated clinical data.
Bimetra Biobank is located in Ghent, Belgium.
Latitude: 51° 14′ 31.242″
Longitude: 3° 43′ 25.8024″
Retrospective collections since 2001.
Prospective collections gradually being built.
Temporal coverage for accessibility
Prospective collections are ongoing. No foreseen date of closure.
The Bimetra Biobank has implemented a quality management system, based on the harmonized quality guidelines for biobanks from the Flemish Biobank Initiative, developed in 2010 . In the absence of a specific international quality standard for biobanking, the Flemish Biobank Network (former CMI, Centre For Medical Innovation) set out to make a set of quality standards, based on ISO 9001:2008, ISBER Best Practices for Repositories  (version 2, 2008), the OECD Best Practice Guidelines for Biological Resource Centres (2007) , the WHO International Agency for Research on Cancer (IARC) Common minimum technical standards and protocols for biological resource centres dedicated to cancer research (2007) and the French standard NF S 96–900. Each CRC biobank of the Flemish Biobank Network implemented these quality standards and was positively peer review audited by the end of 2014.
Since 2012, Bimetra Biobank has implemented a professional software system (IProva, Infoland) for document management (iDOCs) and registration of corrective and preventive actions (CAPA registration, IML) as a sound basis for the Quality Management System (QMS). Through the use of iDOCs, all documents pertaining to the QMS are kept in an electronic and web-based system, localized on a central server and through integrated user management, it is guaranteed that all authorised employees have access to the latest up-to-date documents. This system is used for development, management, controlled access, archiving and training of staff of all biobank related processes. This ranges from administrative processes, such as purchasing of consumables, facility access and training procedures, to operational processes, such as processing of samples, registration and follow-up of non-conformities and transport procedures. Furthermore, all performed procedures and flows are translated in specific SOPs, assuring high quality sample processing and storage. Additionally, every process step including specific processing information, storage conditions and details, are recorded in the ELN of the database management system of the biobank, SLims. Samples processed specifically at the Bimetra Biobank have real-time input of the data in the ELN module. By customisation and further development in SLims of a custom database flow, an overall integrated data collection flow is achieved, allowing to generate automatically SPREC codes. Due to practical considerations regarding the sample quality, some samples are processed at other locations, and input of the data regarding processing is then captured through file transfer in order to generate the correct SPREC codes.
Sample processing follows general standard guidelines and procedures as shown in Table 1. However, within the setting of specific large-scale clinical trials, samples can be collected and processed with specific adapted procedures that are optimised for downstream analysis. The specifications of the adapted procedures are also registered in the ELN to keep a full traceability of the procedures followed. Access to biospecimens is possible in collaboration with the responsible researchers for well-defined purposes. Requests for storage and access should be forwarded to the Biobank Manager.
|Type||sample type||primary collection tube||Processing||Freezing||Aliquots||Storage (main storage)|
|liquid sample||serum||serum separation tube with clot activator||1500 g at RT, 10 min||slow rate freezing, ULT||3 to 6||–80°C|
|liquid sample||plasma||Potassium EDTA tube||815 g, 4°C, 10 min and 2500 g, 4°C, 10 min||slow rate freezing, ULT||3 to 6||–80°C|
|liquid sample||plasma low platelet||Potassium EDTA tube||3200 g at RT, 12 min and 2000 g, 4°C, 10 min||slow rate freezing, ULT||3 to 6||–80°C|
|liquid sample||plasma and RBC rest||Potassium EDTA tube||815 g, 4°C, 10 min and 2500 g, 4°C, 10 min||slow rate freezing, ULT||3 to 6||–80°C|
|liquid sample||buffy coat, viable PBMC||Potassium EDTA tube||buffy coat separation with Lymphoprep||controlled rate freezing, ULT||up to 20||isothermal freezer|
|liquid sample||cell lines||NA||NA||controlled rate freezing, device||1 to 10||isothermal freezer|
|liquid sample||urine||30 ml PP tube||aliquoting||slow rate freezing, ULT||1||–80°C|
|liquid sample||semen||straws||aliquoting||controlled rate freezing, device||multiple||isothermal freezer|
|liquid sample||reproductive material||cryovials and straws||aliquoting||controlled rate freezing, device||multiple||isothermal freezer|
|solid sample||stool||30 ml PP tube and 1.5 ml PP tube||weighing and aliquoting||slow rate freezing, ULT||1 to 10||–80°C|
|solid sample||frozen tissue, tumor||NA||macroscopical dissection and freezing||snapfreezing isopenthane||1 to 5||–80°C|
|solid sample||frozen tissue, normal||NA||macroscopical dissection and freezing||snapfreezing isopenthane||1 to 5||–80°C|
|solid sample||frozen tissue, other||NA||macroscopical dissection and freezing||snapfreezing isopenthane||1 to 5||–80°C|
|solid sample||FFPE tissue||NA||formalin fixation and parafin embedding||NA||1 to 5||RT|
|solid sample||reproductive material||cryovials||macroscopical dissection and freezing||controlled rate freezing, device||multiple||isothermal freezer|
Samples can be delivered at the Bimetra Biobank in different collection recipients, as indicated in Table 1. After sample processing, samples are stored in standard barcoded cryovials of 1.8 ml, 4 ml or 5 ml, aluminium cryocups of 3 to 5 ml, straws, stabilizer tubes (Paxgene tubes) or biobanking tubes of 300 or 600 µl. The type of storage is dependent on the specific needs of the research project and requests from the researchers.
Type of long-term preservation
Frozen samples: in access-controlled and temperature-monitored facility with locked –80°C freezers and isothermal freezers (LN2).
FFPE tissue samples: in access controlled and temperature-monitored storage cabinets.
Isothermal freezers (–170°C to –190°C), –80°C, –35°C, –20°C, 4°C, room temperature (18°C–25°C).
Shipping temperature from patient/source to preservation or research use
0–4°C (on ice); room temperature (18–25°C).
Shipping temperature from storage to research use
–170°C to –190°C (liquid nitrogen), –80°C (on dry ice); 0 –4°C (on ice); room temperature (18–25°C).
Quality assurance measures
Samples are processed according to harmonized procedures (SOPs), by trained staff. All process steps are recorded into the ELN of the sample- and data management system, automatically generating the appropriate SPREC Code. The SPREC codes are a general indicator of the sample quality and the appropriateness of a sample to be included in specific types of analysis.
Yearly, a quality check of general tissue and liquid samples is performed. Specific care is taken into account for selection of the samples to be sacrificed for the quality control procedure, so that unique and rare samples are never accidentally selected.
Principal measures for ensuring the quality of samples:
- Govern the suitability of reagents and laboratory materials.
- Ensure an immediate intervention in case of an electrical blackout to safeguard samples with proper alarm systems for all freezers.
- Have a risk-management storage system for each sample in separate freezers.
- Maintain the database up-to-date.
Checks that are performed:
- DNA extraction, quantification and integrity check with DNA Integrity Number (DIN) assessment
- RNA extraction, quantification and integrity check with RNA Integrity Number (RIN) assessment
- Buffy coats: viability checks
When samples are requested, dependent on the type of sample, additional checks are performed.
- all samples:
- ◦ location check
- ◦ check of required volume and amount of aliquots
- ◦ check of the SPREC code and appropriateness with regard to the specific analysis
- tissue samples:
- ◦ preparation of a cryosection with Hematoxylin and Eosin (H&E) staining
- ◦ evaluation performed by a pathologist
In 2016, the Bimetra Biobank participated in the Integrated Biobank of Luxembourg (IBBL) proficiency testing (ISBER endorsed) for DNA extraction from tissues, DNA quantification, RNA extraction from tissues, RNA quantification and buffy coat preparation. The Bimetra Biobank performed very satisfactory in all categories.
Source of associated data
As mentioned before, the Bimetra Biobank has implemented several minimal datasets:
- for tumour related material: tumour biobank minimal dataset with ICD-O3 coding and TNM Classification of Malignant Tumours (TNM) coding
- for other collections: Flemish Biobank Network minimal dataset with ICD-10 coding for diseases
Both minimal datasets also include all parameters needed to generate the SPREC coding. All this data is recorded and kept in the sample- and data management system, SLims. The system is customised according to the Bimetra Biobank specific needs. Furthermore, the minimal dataset can be extended to project specific datasets. Patient and disease related data is collected through automatic data retrieval from several linked databases, such as the electronic patient health records and pathology records. These database connections are strictly project specific and established after all legal and ethical approvals are obtained. The automatic data retrieval minimizes the risks in mistakes or misidentifications. This data can be completed with data from questionnaires and laboratory analysis, inputted manually or through coupling with electronic Case Report Form (eCRF) modules.
To improve accessibility and visibility of the samples and data sharing for translational clinical research, the Flemish Biobank Network has recently set up a catalogue of biobank samples . The catalogue maps different data sets and subsets from autonomous database systems enabling aggregated query results and threshold induced notifications for participating researchers (Figure 3). At each Partner Biobank within the Network, harmonized datasets are uploaded to a local Opal database. Aggregated results of a subset of the variables is made available to the central catalogue, Mica (referred to as the central backbone in figure), which is query able in real-time through the online catalogue. A verified email address suffices for querying the Minimal Data Set of 12 variables. Query terms can be added using real-time filtering of ontologies (ICD-10, ICD-O-3) or aided by statistics of the variable. No individual-level data passes through Mica (the central backbone), yet researchers can assess the suitability of a dataset for their needs. The results are shown as grouped data with a total result of matching samples to query data. The sample can be requested through sample access flows, specific to each partner of the Flemish Biobank Network.
All collections managed within the Bimetra Biobank have been established in the context of a predefined research project for which an Institutional Ethical Review Board approval was obtained. All projects comply with the Declaration of Helsinki (Ethical Principles for Medical Research Involving Human Subjects) and the Good Clinical Practice (GCP) regulation and Data protection regulations.
Primary use of samples is accepted only within the predefined research goals, secondary use is subject to a revised Ethical Board approval and in addition the donors need to be recontacted to reconsent to the secondary purposes. All data related to the donor collected in the database system, are pseudonymised. The database system, Slims, implies a coding strategy which is compliant with current privacy regulations, and will be updated for implementation of GDPR.
(3) Bioresource description
Bimetra Biobank UZ Gent
De Pintelaan 185 -1DWR
The Bimetra Biobank is located at Ghent University Hospital. The central biobank facility is located at DWR, -1 (basement). There are multiple sample collection points at the University Hospital, such as the Pathology Department for tissue samples and the central clinical lab for blood, serum and plasma samples.
BE_71067049; Bimetra Biobank @ UZ Gent, BBMRI-ERIC
The Bimetra Biobank is a central hospital integrated biobank, comprising of a number of disease-oriented biobanks, population-based biobanks and basic research collections.
- Disease-oriented biobanks:
- ◦ Hepatotropic pathogens: HCV and HBC
- ◦ Inflammatory Bowel Diseases: Colitis Ulcerosa, Crohn’s disease
- ◦ Rheumatoid arthritis
- ◦ Chronic Obstructive Pulmonary Disease (COPD)
- ◦ Chronic Renal failure
- ◦ Neurodegenerative diseases: Multiple Sclerosis
- ◦ Cancer related collections
- Cancer tissue bank (solid tumours): prostate cancer, breast cancer, urothelial cancer, cervix cancer, lung cancer…
- Cancer serum collection
- Pediatric hemato-oncology biobank
- Population based biobanks:
- ◦ Asklepios collection (cardiovascular risk factors and aging (longitudinal cohort))
- ◦ Twin registry (East-Flemish Twin register)
- ◦ Hepatotropic pathogens: population serum collection
- Basic research collections
- ◦ Human embryonic stem cells and iPS cells for stem cell research
- ◦ Reproductive health collections
- ◦ Cancer cell line collections (human): primary and immortalized
Type of sampling
Operational management of multiple type collections:
- population-based cohort collections with longitudinal follow-up
- disease-based collections
- hospital-based clinical collections (residuary material after diagnosis)
- hospital-based clinical trial collections
- tumour biobank collections
Several anatomical sites in the body are covered, depending on the focus of the collection.
Disease status of patients/source
Clinical characteristics of patients/source
As mentioned in the associated data, a minimal dataset is accessible for each sample in the Bimetra Biobank, with inclusion of ICD-10 or ICD-O3 and TNM Classification of Malignant Tumours codes (for tumour related samples). Project specific extended datasets with multiple clinical parameters and questionnaire information can be made available in the research collaboration, depending on the type of collection and the criteria followed for sample and data collection.
Vital state of patients/source
Alive at time of sampling.
Small collection of post-mortem samples.
Clinical diagnosis of patients/source
Available in dataset: ICD-10 or ICD-O3 classification.
Healthy collections and disease-based collections.
Available in dataset when applicable.
Control samples are available in multiple specific collections. Most frozen residual tumour samples are stored with matching normal tissue. Several collections have healthy control samples available.
A different variety of samples is available, depending on the specific project and related research settings, such as serum, plasma, platelet low plasma, viable Peripheral Blood Mononuclear Cells (PBMCs), tissue, cells, DNA, RNA, cell lines, urine, stool…
Size of the bioresource
Bimetra Biobank is not a project, but is part of the CRC Bimetra and has no fixed expiry date. The size of each project collection within the Bimetra Biobank varies. In general, about 120.000 samples are currently present in the Bimetra Biobank, originating from different research projects and in collaboration with multiple researchers, comprising both prospective and historical collections. In Figures 4 and 5, an overview of the amount of stored samples and distribution of samples can be found.
Data and samples in the collections are available within the context of well-defined research collaborations in consensus with all parties involved.
Samples and associated data from collections within the Bimetra Biobank can be applied for further biomedical research. A sample request can be launched through the Flemish Biobank Backbone , through the sample locator of BBMRI (national node BBMRI.be) or by filling in the sample request form on the Bimetra biobank website , using a set of minimal parameters. Every researcher worldwide can send in a request to the Biobank.
Bimetra Biobank will facilitate downstream processes regarding the sample request (such as contacting the coordinator of the collection and sample flow release, assistance and (p)review of an IRB approval to ensure that the planned methods on the requested samples are ethically sound, research agreement negotiations, QC control of the requested material and sample transport). In addition, Bimetra Biobank has implemented and executed SOPs for retrieval of samples and data within its quality management system. The Bimetra Biobank will act as a trusted third party collaboration, ensuring patient/donor coding/anonymity.
The costs will vary related to the type and amount of samples that are shipped and the specific data that is requested, as is set out in the research agreement with integrated Material Transfer Agreement (MTA)/Data Transfer Agreement (DTA).
(4) Reuse potential
Samples and data in the Bimetra Biobank collections can be used in different scientific projects. A sample request can be launched by filling in the sample request form on the Bimetra biobank website . Additional clinical data related to Biobank samples can be traced through the electronic health record systems via the treating physician or the medical ‘controller’ (as following Belgian legislation concerning the requirements for collection, storage and use of human bodily material for research purposes), and aligned with the IRB approval and the provisions in the research collaboration agreements on the sample and data use.
In sample distribution, Bimetra Biobank acts as a trusted third party, ensuring donor anonymity by coding of the samples. The applicant must follow the agreements made in the MTA/DTA with the primary researchers of the collection and acknowledge the Bimetra Biobank, according to the COBRA guidelines  for standardised biorepository citations. The actual citation for each collection, with unique reference number, is specified in the MTA agreement.